A Prospective Research Study of Anti-Glaucoma Drugs Prescribing, Utilization Pattern and Adverse Drug Reaction Recording in a University Hospital

Abstract

Objective: This study was carried out to evaluate the drug prescribing, utilization pattern and adverse drug reactions recording associated with drugs prescribed to glaucoma patients.

Materials and Methods: A total of 50 glaucoma patients were included in the study, based on inclusion and exclusion criteria. All the observations were recorded in drug utilization and ADR recording documentation form.

Results: Out of 50 patients suffering from glaucoma, 38 patients (76%) were diagnosed open angle glaucoma, 4 patients (8%) closed angle glaucoma and 8 patients (16%) post-operative respectively. There were 19 patients (38%) males and 31 patients (62%) were females. The age range between 41–50 years had the maximum number of patients 15 (30%). A total of 17 patients (34%) had family history of glaucoma. Timolol was prescribed to 34 patients (68%), followed by dorzolamide 18 patients (36%) and acetazolamide 14 patients (28%). A total of 32 patients (64%) were prescribed single drug therapy whereas 18 patients (36%) were on multiple drug therapy. A total of 25 patients (50%) reported ADR. In the present study, latanoprost was associated with maximum number of ADRs 9 patients (18%) followed by acetazolamide 7 patients (14%), dorzolamide 4 patients (8%), then timolol 3 patients (6%) and pilocarpine 2 patients (4%). According to Naranjo scale, in 6 patients (24%) the ADR were unlikely, 12 patients (48%) were given possible score, 3 patients (12%) were given probable score, and 4 patients (16%) were given definite scores.

Conclusion: In the present study, the maximum patients were in the age group of 41–50 years. The most commonly prescribed drugs were timolol followed by dorzolamide, acetazolamide. Latanoprost was associated with maximum number of ADRs.

Key words

ADR - anti-glaucoma drugs - timolol - Naranjo scale

• References

• 1 Pizzarello L, Abiose A, Ffytche T et al. Vision 2020: The Right to Sight: a global initiative to eliminate avoidable blindness. Arch Ophthalmol 2004; 122: 615-620
• 2 Yadav AK, Patel V. Drugs used in primary open angle glaucoma: A prospective study at a tertiary care teaching hospital. IJP 2013; 45: 117-120
• 3 Ravinet E, Bovey E, Mermoud A. T-Flux implant versus Healon GV in deep sclerectomy. J Glaucoma 2004; 13: 46-50
• 4 Detry-Morel M, Detry MB. Five-year experience with non penetrating deep sclerectomy. Bull Soc Belge Ophtalmol 2006; 299: 83-94
• 5 Rebolleda G, Munoz-Negrete FJ. Deep sclerectomy with mitomycin C in failed trabeculectomy. Eye 2007; 21: 23-28
• 6 Mousa AS. Preliminary evaluation of non-penetrating deep sclerectomy with autologous scleral implant in open-angle glaucoma. Eye 2007; 21: 1234-1238
• 7 Singh K, Das J. Use of amniotic membrane vs. mitomycin in trabelectomy. V^th International Glaucoma Symposium. Cape Town, South Africa: 30^th March–2^nd April 2005
• 8 Moreno-Lopez M, Perez-Alvarez MJ. Short- and medium-term intraocular pressure lowering effects of combined phaco emulsification and non-penetrating deep sclerectomy without scleral implant or antifibrotics. Arch Soc Esp Oftalmol 2006; 81: 93-100
• 9 Varma R, Ying-Lai M, Francis BA et al. Prevalence of open-angle glaucoma and ocular hypertension in Latinos: the Los Angeles Latino Eye Study. Ophthalmology 2004; 111: 1439-1448
• 10 Mermoud A. Non-penetrating surgery. In: Shaarawy T, Mermoud A. eds. Atlas of glaucoma surgery. Vol II. New Delhi: Jaypee Brothers Medical (Publishers P) Ltd., India; 2006: 103-130
• 11 Friedman DS, Wolfs RC, O’Colmain BJ et al. Eye Diseases Prevalence Research Group . Prevalence of open-angle glaucoma among adults in the United States. Arch Ophthalmol 2011; 129: 1224
• 12 Zhong H, Li J, Li C et al. The prevalence of glaucoma in adult rural Chinese populations of the Bai nationality in Dali: the Yunnan Minority Eye Study. Invest Ophthalmol Vis Sci 2012; 53 3221-3225
• 13 Raychaudhuri A, Lahiri SK, Bandyopadhyay M et al. A population based survey of the prevalence and types of glaucoma in rural West Bengal: the West Bengal Glaucoma Study. Br J Ophthalmol 2005; 89: 1559-1564
• 14 Agarwal S, Shamshad MA, Goel D et al. Distribution of Glaucoma in the Major Religious Communities of a Northern Indian Town: A Hospital Survey. Journal of Clinical and Diagnostic Research 2013; 7: 499-502
• 15 Resnikoff S, Pascolini D, Etya’ale D et al. Global data on visual impairment in the year 2002. Bulletin of the World Health Organization. 2004 82. 844-851
• 16 Lingam V, Ronnie G, Baskaran M et al. Prevalence of Primary Open-angle Glaucoma in an Urban South Indian Population and Comparison with a Rural Population. The Chennai Glaucoma Study. Ophthalmology 2008; 115: 648 - 654
• 17 Tielsch JM, Katz J, Sommer A et al. Family history and risk of primary open angle glaucoma. The Baltimore Eye Survey Arch Ophthalrmol 1994; 11: 69-73
• 18 Uhm K-B, Shin DH. Positive Family History or Glaucoma is a Risk Factor for Increased IOP rather than Glaucomatous Optic Nerve Damage. Korean J Ophthalmol 1992; 6: 100-104
• 19 Amera Singh N, Wong TY, Wong WL et al. Determinants of the optic cup to disc ratio in an Asian population: The Singapore Malay Eye Study. Arch Opthalmol 2008; 126: 1101-1108
• 20 Webers CA, Beckers HJ, Nuijts RM et al. Pharmacological management of primary open-angle glaucoma: second-line options and beyond. Drugs Aging 2008; 25: 729-759
• 21 Hommer Anton. Role of Fixed Combinations in the Management of Open-angle Glaucoma. Expert Rev Pharmacoeconomics Outcomes Res 2011; 11: 91-99
• 22 David A, Harvey R, John G. Diagnosis and management of open angle glaucoma. Ophthalmology 2002; 15: 23-28
• 23 Odberg T. Visual field prognosis in early glaucoma. A long-term clinical follow-up. Acta Ophthalmologica 1993; 71: 721-726
• 24 Renieri G, Führer K, Scheithe K et al. Efficacy and Tolerability of Preservative-Free Eye Drops Containing a Fixed Combination of Dorzolamide and Timolol in Glaucoma Patients. J Ocul Pharmacol Ther 2010; 26: 597-603